Understanding Vision Loss Risk in Geographic Atrophy
For members of the inherited retinal disease and broader retinal community, understanding how specific conditions progress over time is critical for managing patient care and expectations. Recent findings presented at scientific meetings offer a closer look at how baseline eye characteristics influence disease trajectories in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Key Findings from the ARCHER Study Analysis
According to coverage by Ophthalmology Times Europe, Dr. Margaret Chang, MD, MS, discussed new baseline predictors of vision loss from the phase 2 ARCHER study of vonaprument during the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting. While the primary endpoint of the trial measured GA lesion size via fundus autofluorescence, researchers also evaluated secondary functional measures such as best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA).
In a post hoc analysis, Dr. Chang and her colleagues reported that eyes with a baseline visual acuity ranging between approximately 20/40 and 20/100, as well as those featuring subfoveal rather than extrafoveal lesions, faced the highest likelihood of experiencing a loss of 15 or more ETDRS letters over a 12-month period. Conversely, factors such as baseline age, total lesion size, and other evaluated medical or ocular history variables did not show an association with this specific degree of vision loss.
Implications for Patient Counseling and Clinical Trials
These insights provide clearer parameters for clinicians when discussing prognosis with individuals affected by geographic atrophy. Patients presenting with visual acuity better than 20/40 demonstrated a higher probability of preserving their vision over the following year, while those with acuity worse than 20/100 tended to remain relatively stable. Furthermore, these findings helped inform enrollment criteria for the ongoing phase 3 ARCHER II trial.
Looking Ahead
As clinical research in degenerative retinal conditions continues to evolve, investigators are placing an increased emphasis on functional, patient-centered visual measures alongside structural endpoints. Future updates from subsequent trial phases will continue to shed light on therapeutic developments and prognostic markers for retinal disease communities.